 Midazolam
"Midazolam" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
| Descriptor ID |
D008874
|
| MeSH Number(s) |
D03.633.100.079.080.575
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Midazolam".
Below are MeSH descriptors whose meaning is more specific than "Midazolam".
This graph shows the total number of publications written about "Midazolam" by people in this website by year, and whether "Midazolam" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 1 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 2 | 3 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 3 | 4 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Midazolam" by people in Profiles.
-
Farrar JE, Stefanos SS, Cava L, Kiser TH, Mueller SW, Neumann R, Reynolds PM, Sherman DS, MacLaren R. Correlation Between Serum and CSF Concentrations of Midazolam and 1-Hydroxy-Midazolam in Critically Ill Neurosurgical Patients. Ann Pharmacother. 2025 Mar; 59(3):244-249.
-
Miller C, Sommavilla R, O'Bryant CL, Barve M, Dowlati A, Luke JJ, Khatun M, Morris T, Cullberg M. Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2024 Aug; 94(2):223-235.
-
Ward CE, Adelgais KM, Holsti M, Jacobsen KK, Simon HK, Morris CR, Gonzalez VM, Lerner G, Ghaffari K, VanBuren JM, Lerner EB, Shah MI. Public support for and concerns regarding pediatric dose optimization for seizures in emergency medical services: An exception from informed consent (EFIC) trial. Acad Emerg Med. 2024 07; 31(7):656-666.
-
Mariotti AL, Pattee J, Edmundowicz SA, Hardesty TD, Sharma SM, Lemley MG, Rist SD, Weitzel N, Faruki AA. Operational outcomes of propofol sedation versus fentanyl, midazolam and diphenhydramine sedation for endoscopies and colonoscopies at an academic medical center. PLoS One. 2023; 18(11):e0294418.
-
Tuey SM, Prebehalla L, Roque AA, Roda G, Chonchol MB, Shah N, Wempe MF, Hu Y, Hogan SL, Nolin TD, Joy MS. The Impact of Suboptimal 25-Hydroxyvitamin D Levels and Cholecalciferol Replacement on the Pharmacokinetics of Oral Midazolam in Control Subjects and Patients With Chronic Kidney Disease. J Clin Pharmacol. 2022 Dec; 62(12):1528-1538.
-
Rappaport LD, Markowitz G, Hulac S, Roosevelt G. Medication Errors in Pediatric Patients after Implementation of a Field Guide with Volume-Based Dosing. Prehosp Emerg Care. 2023; 27(2):213-220.
-
Baldassari MP, Mouchtouris N, Velagapudi L, Nauheim D, Sweid A, Saiegh FA, Khanna O, Ghosh R, Herman M, Wyler D, Gooch MR, Tjoumakaris S, Jabbour P, Rosenwasser R, Romo V. Comparison of Anesthetic Agents Dexmedetomidine and Midazolam During Mechanical Thrombectomy. J Stroke Cerebrovasc Dis. 2021 Dec; 30(12):106117.
-
Forbes N, Chau M, Koury HF, Lethebe BC, Smith ZL, Wani S, Keswani RN, Elmunzer BJ, Anderson JT, Heitman SJ, Hilsden RJ. Development and validation of a patient-reported scale for tolerability of endoscopic procedures using conscious sedation. Gastrointest Endosc. 2021 07; 94(1):103-110.e2.
-
Gile J, Oyama Y, Shuff S, Eckle T. A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction. Curr Pharm Des. 2020; 26(34):4330-4337.
-
Wheeler AR, Schauer SG, April MD, De Lorenzo RA. Acute Agitation and the Exception From Informed Consent Requirements. Ann Emerg Med. 2019 06; 73(6):691-692.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|